FL1
MCID: FLL041
MIFTS: 44

Follicular Lymphoma 1 (FL1)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma 1

MalaCards integrated aliases for Follicular Lymphoma 1:

Name: Follicular Lymphoma 1 57 29
Follicular Lymphoma, Susceptibility to, 1 57 13
Lymphoma, Follicular, Type 1 39
Lymphoma, Follicular 70
Follicular Lymphoma 58
Fl1 57

Characteristics:

Orphanet epidemiological data:

58
follicular lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

HPO:

31
follicular lymphoma 1:
Inheritance polygenic inheritance


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

OMIM® 57 613024
MESH via Orphanet 45 D008224
UMLS via Orphanet 71 C0024301
Orphanet 58 ORPHA545
MedGen 41 C2751665
UMLS 70 C0024301

Summaries for Follicular Lymphoma 1

OMIM® : 57 Follicular non-Hodgkin lymphoma is an indolent B-cell malignancy with an annual incidence exceeding 10,000 cases in the United States (Bohen et al., 2003). One form of susceptibility to follicular lymphoma (FL1) is associated with a region on chromosome 6p21.33. (613024) (Updated 05-Apr-2021)

MalaCards based summary : Follicular Lymphoma 1, also known as follicular lymphoma, susceptibility to, 1, is related to lymphoma, non-hodgkin, familial and b-cell lymphoma. An important gene associated with Follicular Lymphoma 1 is BCL2 (BCL2 Apoptosis Regulator), and among its related pathways/superpathways are Toxoplasmosis and Tuberculosis. The drugs Neuroprotective Agents and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are splenomegaly and fatigue

Related Diseases for Follicular Lymphoma 1

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 31.6 IGH BCL6 BCL2
2 b-cell lymphoma 31.1 IGH BCL6 BCL2
3 lymphoma, hodgkin, classic 31.0 BCL6 BCL2
4 marginal zone b-cell lymphoma 31.0 BCL6 BCL2
5 nodal marginal zone b-cell lymphoma 30.7 BCL6 BCL2
6 mantle cell lymphoma 30.6 IGH BCL6 BCL2
7 nodal marginal zone lymphoma 30.5 IGH BCL6
8 primary central nervous system lymphoma 30.4 BCL6 BCL2
9 follicular lymphoma 30.3 IGH FL1 BCL6 BCL2
10 leukemia, chronic lymphocytic 30.2 IGH BCL6 BCL2
11 lymphosarcoma 30.2 IGH BCL6 BCL2
12 lymphoma, mucosa-associated lymphoid type 30.1 IGH BCL6 BCL2
13 intravascular large b-cell lymphoma 30.1 BCL6 BCL2
14 lymphoplasmacytic lymphoma 30.0 IGH BCL6
15 t-cell/histiocyte rich large b cell lymphoma 30.0 IGH BCL6
16 leukemia, acute lymphoblastic 29.8 IGH BCL6 BCL2
17 reticulosarcoma 29.7 IGH BCL6 BCL2
18 primary cutaneous follicle center lymphoma 11.1
19 lymphoma 11.1
20 histiocytic and dendritic cell cancer 11.1
21 diffuse large b-cell lymphoma 11.1
22 burkitt lymphoma 10.7
23 neutropenia 10.7
24 lymphoblastic lymphoma 10.5
25 leukemia 10.5
26 myelodysplastic syndrome 10.5
27 b-cell non-hodgkin lymphoma 10.5
28 splenomegaly 10.4
29 splenic marginal zone lymphoma 10.4
30 thrombocytopenia 10.4
31 lymphoma aids related 10.4
32 lymphoproliferative syndrome 10.4
33 sarcoma 10.4
34 spindle cell sarcoma 10.4
35 chromosomal triplication 10.4
36 plasmablastic lymphoma 10.4
37 graft-versus-host disease 10.4
38 pemphigus 10.4
39 leukemia, acute myeloid 10.4
40 paraneoplastic pemphigus 10.4
41 composite lymphoma 10.4
42 lymphopenia 10.4
43 47,xyy 10.4
44 lymphomatoid granulomatosis 10.4
45 myeloid leukemia 10.3
46 indolent b cell lymphoma 10.3
47 cll/sll 10.3
48 progressive multifocal leukoencephalopathy 10.3
49 progressive transformation of germinal centers 10.3
50 adenocarcinoma 10.3

Graphical network of the top 20 diseases related to Follicular Lymphoma 1:



Diseases related to Follicular Lymphoma 1

Symptoms & Phenotypes for Follicular Lymphoma 1

Human phenotypes related to Follicular Lymphoma 1:

58 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Frequent (79-30%)
2 fatigue 58 Frequent (79-30%)
3 fever 58 Very frequent (99-80%)
4 lymphedema 58 Occasional (29-5%)
5 lymphoma 58 Very frequent (99-80%)
6 meningitis 58 Occasional (29-5%)
7 weight loss 58 Very frequent (99-80%)
8 mediastinal lymphadenopathy 58 Very frequent (99-80%)
9 abnormality of the peritoneum 58 Occasional (29-5%)
10 pleural effusion 58 Occasional (29-5%)
11 lymphadenopathy 58 Very frequent (99-80%)
12 skin nodule 58 Occasional (29-5%)
13 night sweats 58 Very frequent (99-80%)
14 follicular lymphoma 31 HP:0033125

Clinical features from OMIM®:

613024 (Updated 05-Apr-2021)

Drugs & Therapeutics for Follicular Lymphoma 1

Drugs for Follicular Lymphoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neuroprotective Agents Phase 4
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Teniposide Approved Phase 3 29767-20-2 34698
8
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
9
Promethazine Approved, Investigational Phase 3 60-87-7 4927
10
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
11
Acetaminophen Approved Phase 3 103-90-2 1983
12
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
13
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
14
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
15
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
18
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
19
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
20
Idelalisib Approved Phase 3 870281-82-6
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
23
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
24
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
25
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
26
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
27
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
28
Pixantrone Approved, Investigational Phase 3 144510-96-3
29
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
32
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
34
Fotemustine Investigational Phase 3 92118-27-9
35
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
36
Galiximab Investigational Phase 3 357613-77-5
37 Antibiotics, Antitubercular Phase 3
38 Anti-Bacterial Agents Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Interleukin-2 Phase 3
41 Protective Agents Phase 3
42
Liposomal doxorubicin Phase 3 31703
43 Interferon alpha-2 Phase 3
44 Anti-Infective Agents, Local Phase 3
45 Neurotransmitter Agents Phase 3
46 Histamine Antagonists Phase 3
47
Histamine Phosphate Phase 3 51-74-1 65513
48 Histamine H1 Antagonists Phase 3
49 Antipyretics Phase 3
50 Calciferol Phase 3

Interventional clinical trials:

(show top 50) (show all 583)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma Active, not recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine
3 Prospective Multicenter Study: Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma Unknown status NCT02423837 Phase 3 Rituximab, bendamustine
4 A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma Unknown status NCT02260804 Phase 3
5 MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA Unknown status NCT00435955 Phase 3 Rituximab
6 Phase III Multicentric IIL Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Treatment of Patients With Stage II-IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
8 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
9 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
10 Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial Unknown status NCT00028691 Phase 3 chlorambucil
11 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
12 Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
13 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
14 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Completed NCT02213263 Phase 3
15 Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
16 An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Completed NCT01059630 Phase 3 Obinutuzumab;Bendamustine
17 A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma Completed NCT02809053 Phase 3
18 A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma Completed NCT02162771 Phase 3 Cyclophosphamide;Vincristine;Prednisone
19 A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen Completed NCT02569996 Phase 3 Rituximab
20 Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy Completed NCT00140582 Phase 3 Rituximab
21 Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
22 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
23 Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden Completed NCT00696735 Phase 3
24 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
25 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
26 FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden Completed NCT00136552 Phase 3 rituximab
27 A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV Completed NCT01200758 Phase 3 Rituximab SC;Rituximab IV;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone/Prednisolone
28 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
29 Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial Completed NCT00227695 Phase 3
30 Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
31 A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
32 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
33 A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
34 Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial Completed NCT00185393 Phase 3
35 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
36 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
37 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
38 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
39 A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
40 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
41 A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial Recruiting NCT02438501 Phase 3
42 Dose Optimization Study of Idelalisib in Follicular Lymphoma Recruiting NCT02536300 Phase 3 Idelalisib
43 A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma Recruiting NCT03976102 Phase 3
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Recruiting NCT04680052 Phase 3 tafasitamab;rituximab;lenalidomide;placebo
45 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE) Recruiting NCT02947347 Phase 3 ibrutinib;placebo to match ibrutinib;rituximab;ibrutinib;placebo to match ibrutinib;placebo to match ibrutinib
46 A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Recruiting NCT04224493 Phase 3 Tazemetostat;Placebo oral tablet
47 Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial Recruiting NCT02449252 Phase 3 cyclophosphamide;doxorubicin;vincristine;prednisone
48 A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements Recruiting NCT04799275 Phase 2, Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
49 ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Supplemental Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Recruiting NCT03078855 Phase 3
50 A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT). Recruiting NCT02390869 Phase 3 R2-MANT;R-MANT

Search NIH Clinical Center for Follicular Lymphoma 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ibritumomab tiuxetan

Genetic Tests for Follicular Lymphoma 1

Genetic tests related to Follicular Lymphoma 1:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 1 29

Anatomical Context for Follicular Lymphoma 1

MalaCards organs/tissues related to Follicular Lymphoma 1:

40
T Cells, Bone, Bone Marrow, Liver, Myeloid, Nk Cells, Lymph Node

Publications for Follicular Lymphoma 1

Articles related to Follicular Lymphoma 1:

(show all 28)
# Title Authors PMID Year
1
Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. 57
23791106 2013
2
Integrating GWAS and expression data for functional characterization of disease-associated SNPs: an application to follicular lymphoma. 57
23246294 2013
3
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. 57
20639881 2010
4
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. 57
19620980 2009
5
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. 57
12571354 2003
6
BCL2 translocation frequency rises with age in humans. 57
8090743 1994
7
bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. 57
2648153 1989
8
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. 57
3287162 1988
9
The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. 57
2965608 1988
10
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. 57
3110950 1987
11
Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. 57
3537802 1987
12
Involvement of the bcl-2 gene in human follicular lymphoma. 57
3874430 1985
13
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. 57
6334305 1984
14
Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. 57
6605167 1983
15
Mapping of an endogenous retroviral sequence to human chromosome 18. 57
6843662 1983
16
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. 57
7133054 1982
17
Use of Smooth Muscle Myosin Heavy Chain as an Effective Marker of Follicular Dendritic Cells. 61
28549038 2019
18
Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. 61
29086453 2018
19
The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. 61
26352106 2016
20
Primary gastrointestinal lymphomas - A study of 81 Cases from a Tertiary Healthcare Centre. 61
25494124 2014
21
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. 61
22496164 2012
22
Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. 61
21736867 2012
23
[Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. 61
20079011 2009
24
Expression of p63 in reactive hyperplasias and malignant lymphomas. 61
16224147 2005
25
Extranodal malignant lymphoma of the upperaerodigestive tract in King Chulalongkorn Memorial Hospital according to WHO classification. 61
16083197 2004
26
[Primary gastric lymphoma]. 61
15483686 2004
27
Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer. 61
12400605 2002
28
Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia. 61
1101936 1975

Variations for Follicular Lymphoma 1

Expression for Follicular Lymphoma 1

Search GEO for disease gene expression data for Follicular Lymphoma 1.

Pathways for Follicular Lymphoma 1

Pathways related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.6 HLA-DRB1 BCL2
2 11.51 HLA-DRB1 BCL2
3 11.28 BCL6 BCL2
4 11.02 BCL6 BCL2
5 10.68 BCL6 BCL2

GO Terms for Follicular Lymphoma 1

Biological processes related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.26 BCL6 BCL2
2 cell morphogenesis GO:0000902 9.16 BCL6 BCL2
3 B cell differentiation GO:0030183 8.96 BCL6 BCL2
4 positive regulation of B cell proliferation GO:0030890 8.62 BCL6 BCL2

Sources for Follicular Lymphoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....